Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma

Ming Wang, Xiangting Bu, Ge Luan, Liqing Lin, Yang Wang, Jianmin Jin, Luo Zhang, Chengshuo Wang, Ming Wang, Xiangting Bu, Ge Luan, Liqing Lin, Yang Wang, Jianmin Jin, Luo Zhang, Chengshuo Wang

Abstract

Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma have more severe disease and are difficult to treat. However, the molecular endotypes associated with CRSwNP with comorbid asthma (CRSwNP + AS) are not clear. This study aimed to investigate the characteristics of type 2 inflammation and the molecular signatures associated with CRSwNP + AS.

Methods: A total of 195 subjects; including 65 CRSwNP + AS patients, 99 CRSwNP-alone patients, and 31 healthy control subjects; were enrolled in the study. Nasal tissues from patients with CRSwNP + AS, CRSwNP-alone and control subjects were assessed for infiltration of inflammatory cells and concentrations of total IgE. Whole-transcriptome sequencing was performed and differentially expressed (DE) mRNAs and long non-coding RNAs (lncRNAs) and their associated pathways were analyzed. The correlations between type 2 cytokines and local eosinophils, tissue IgE, and transcriptome signatures were evaluated.

Results: Significantly higher local eosinophil infiltration and higher levels of total IgE were found in nasal tissues from CRSwNP + AS patients than in nasal tissues from CRSwNP-alone patients. Furthermore, atopy and recurrence were significantly more frequent in patients with CRSwNP + AS than in patients with CRSwNP-alone (62.5% vs 28.6% and 66.7% vs 26.9%, respectively). RNA sequencing analysis identified 1988 common DE-mRNAs, and 176 common DE-lncRNAs shared by CRSwNP + AS versus control and CRSwNP-alone versus control. Weighted gene coexpression network analysis (WGCNA) identified LINC01146 as hub lncRNA dysregulated in both subtypes of CRSwNP. Overall, 968 DE-mRNAs and 312 DE-lncRNAs were identified between CRSwNP + AS and CRSwNP-alone. Both pathway enrichment analysis and WGCNA indicated that the phenotypic traits of CRSwNP + AS were mainly associated with higher activities of arachidonic acid metabolism, type 2 cytokines related pathway and fibrinolysis pathway, and lower activity of IL-17 signalling pathway. Furthermore, the expression of type 2 cytokines; IL5 and IL13, was positively correlated with local eosinophil infiltration, tissue IgE level, and the expression of DE-mRNAs that related to arachidonic acid metabolism. Moreover, WGCNA identified HK3-006 as hub lncRNA in yellow module that most positively correlated with phenotypic traits of CRSwNP + AS.

Conclusions: Patients with CRSwNP + AS have distinct type 2-high inflammation-associated molecular signatures in nasal tissues compared to patients with CRSwNP-alone.

Keywords: Asthma; Chronic rhinosinusitis with nasal polyps; Molecular endotype; Transcriptome sequencing; Type 2 inflammation.

Conflict of interest statement

Competing interestsThe authors declare that they have no conflicts of interest.

© The Author(s) 2020.

Figures

Fig. 1
Fig. 1
Detection of eosinophils and total IgE in blood and nasal tissues from patients with CRSwNP. a, b Blood eosinophils and total IgE was detected in CRSwNP patients with asthma (CRSwNP + AS), CRSwNP-alone and control (Ctrl) subjects. c, d Representative images of haematoxylin and eosin-stained nasal polyp tissues from patients with CRSwNP-alone and CRSwNP + AS. Red arrows point out eosinophils. e The percentage of infiltrating eosinophils, neutrophils, plasma cells and lymphocytes were assessed in nasal tissues of CRSwNP-alone (n = 24) and CRSwNP + AS (n = 25). f Concentrations of total IgE in nasal tissues of Ctrl (n = 10), CRSwNP-alone (n = 14) and CRSwNP + AS (n = 17) were assayed using Human IgE ELISA Kit. Data are presented as medians and interquartile range (IQR). Data shown in a adjusted for smoking, and in b and f adjusted for atopy. *P < 0.05, **P < 0.01, Mann–Whitney U tests. CRSwNP chronic rhinosinusitis with nasal polyps, AS asthma
Fig. 2
Fig. 2
Common dysregulated genes shared by CRSwNP + AS and CRSwNP-alone. Nasal tissue samples of CRSwNP + AS (n = 10), CRSwNP-alone (n = 10), and control (n = 9) were analysed by whole-transcriptome sequencing. a Venn diagrams depicting DE-mRNAs of CRSwNP + AS versus control and CRSwNP-alone versus control. The number of DE-mRNAs is marked in the corresponding areas. b The 1988 common DE-mRNAs shared by CRSwNP + AS versus control and CRSwNP-alone versus control were assessed by pathway enrichment analyses using Enrichr. Top 15 significantly enriched KEGG pathways (blue columns) and top 5 significantly enriched BioCarta pathways (turquoise columns) are depicted. P < 0.05 were considered statistically significant. c Venn diagrams depicting DE-lncRNAs of CRSwNP + AS versus control and CRSwNP-alone versus control. d, e The 176 common DE-lncRNAs shared by CRSwNP + AS versus control and CRSwNP-alone versus control were assessed for expression based modules identified by weighted gene coexpression network analysis (WGCNA) and for their potential functions, based on a coexpression network. e Branches of the dendrogram obtained by hierarchical clustering of adjacency based similarity show 9 modules, labelled with a distinct colour, and d Top 15 significantly enriched KEGG pathways (blue column) and top 5 significantly enriched BioCarta pathways (turquoise column) by genes in the largest turquoise module. f Top 50 hub genes of turquoise module visualized by cytoscape network. mRNAs or lncRNAs with high connectivity and edges with weight above a threshold of 0.1 were identified as hub genes. The red nodes denote lncRNAs, and the green nodes denote mRNAs. CRSwNP chronic rhinosinusitis with nasal polyps, AS asthma, lncRNA long non-coding RNA, DE differentially expressed, KEGG Kyoto Encyclopedia of Genes and Genomes
Fig. 3
Fig. 3
Differentially expressed genes and pathways between CRSwNP + AS and CRSwNP-alone. a Volcano plots illustrating DE-mRNAs of CRSwNP + AS versus CRSwNP-alone identified by RNA sequencing. b Top 15 KEGG pathways (blue column) and top 5 BioCarta pathways (turquoise column) significantly enriched by DE-mRNAs. c The expression of arachidonic acid metabolism-related DE-mRNAs between CRSwNP + AS and CRSwNP-alone. The colour coding of heat maps represents the gene expression level normalized to Control group, calculated based on fragments per kilo-base of exon per million fragments mapped (FPKM). Yellow box indicates the up-regulated genes in CRSwNP + AS group. d The expression of critical cytokines and their receptors that indicated the activity of different inflammatory endotypes. Yellow stars represent significantly differentially expressed genes between CRSwNP + AS and CRSwNP-alone. P < 0.05 were considered statistically significant. CRSwNP chronic rhinosinusitis with nasal polyps, AS asthma, DE differentially expressed, KEGG Kyoto Encyclopedia of Genes and Genomes
Fig. 4
Fig. 4
Correlations between cytokines and inflammatory indicators. Spearman correlation analysis was performed between expression of cytokines IL-5, IL-13, and IL-17A and percentage of local eosinophils, concentration of tissue IgE and LTC4S expression. N = 20 for each group. FPKM fragments per kilo-base of exon per million fragments mapped, IL interleukin-4
Fig. 5
Fig. 5
Differentially expressed lncRNAs and pathway analysis between CRSwNP + AS and CRSwNP-alone. a Volcano plots illustrating DE-lncRNAs of CRSwNP + AS versus CRSwNP-alone identified by RNA sequencing. b The correlation between modules and phenotype of CRSwNP + AS. Seven modules were identified by WGCNA based on expression of DE-mRNAs and DE-lncRNAs of CRSwNP + AS versus CRSwNP-alone. Pearson’s correlation coefficient between each module and phenotype of CRSwNP + AS and their associated P values are shown in the corresponding modules. The red and green colours show a strong positive and negative correlation, respectively. c, d All or top 10 KEGG pathways significantly enriched by genes in blue module c and yellow module (d). e, f Top 50 hub genes in blue module (e) and yellow module (f) visualized by cytoscape network. mRNAs or lncRNAs with high connectivity and edges with weight above a threshold of 0.1 were identified as hub genes. The red nodes denote lncRNAs, and the green nodes denote mRNAs. P < 0.05 were considered statistically significant. CRSwNP chronic rhinosinusitis with nasal polyps; AS: asthma, lncRNA long non-coding RNA, DE differentially expressed, KEGG Kyoto Encyclopedia of Genes and Genomes

References

    1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.
    1. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061–1070.
    1. Hopkins C. Chronic Rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55–63.
    1. Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129(9):1969–1975.
    1. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650.
    1. Sella GCP, Tamashiro E, Sella JA, Aragon DC, Mendonca TN, Arruda LKP, et al. Asthma Is the dominant factor for recurrence in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(1):302–309.
    1. Cho SW, Kim DW, Kim JW, Lee CH, Rhee CS. Classification of chronic rhinosinusitis according to a nasal polyp and tissue eosinophilia: limitation of current classification system for Asian population. Asia Pac Allergy. 2017;7(3):121–130.
    1. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116.
    1. Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373–377.
    1. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897–906.
    1. Samitas K, Carter A, Kariyawasam HH, Xanthou G. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy. 2018;73(5):993–1002.
    1. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45–53.
    1. Wang M, Tan G, Eljaszewicz A, Meng Y, Wawrzyniak P, Acharya S, et al. Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells. J Allergy Clin Immunol. 2019;143(5):1892–1903.
    1. Wang C, Zhang L. Use of biologics in chronic sinusitis with nasal polyps. Curr Opin Allergy Clin Immunol. 2019;19(4):365–372.
    1. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.
    1. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353.
    1. Wang M, Zhang N, Zheng M, Li Y, Meng L, Ruan Y, et al. Cross-talk between TH2 and TH17 pathways in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(5):1254–1264.
    1. Rix I, Hakansson K, Larsen CG, Frendo M, von Buchwald C. Management of chronic rhinosinusitis with nasal polyps and coexisting asthma: a systematic review. Am J Rhinol Allergy. 2015;29(3):193–201.
    1. Wu D, Bleier BS, Li L, Zhan X, Zhang L, Lv Q, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297–1305.
    1. Hakansson K, Thomsen SF, Konge L, Mortensen J, Backer V, von Buchwald C. A comparative and descriptive study of asthma in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(5):383–387.
    1. Qi S, Yan B, Liu C, Wang C, Zhang L. Predictive significance of Charcot-Leyden Crystal mRNA levels in nasal brushing for nasal polyp recurrence. Rhinology. 2020;58(2):166–174.
    1. Li J, Jiao J, Wang M, Gao Y, Li Y, Wang Y, et al. Hypomethylation of the IL8 promoter in nasal epithelial cells of patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(4):993–1003.
    1. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformat. 2013;14:128.
    1. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformat. 2008;9:559.
    1. Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820.
    1. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22.
    1. Tan BK, Klingler AI, Poposki JA, Stevens WW, Peters AT, Suh LA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago. Illinois. J Allergy Clin Immunol. 2017;139(2):699–703.
    1. Avdeeva K, Fokkens W. Precision medicine in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthma Rep. 2018;18(4):25.
    1. Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543–1551.
    1. Lou H, Meng Y, Piao Y, Wang C, Zhang L, Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. Am J Rhinol Allergy. 2015;29(5):350–356.
    1. Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.
    1. Wang ET, Zheng Y, Liu PF, Guo LJ. Eosinophilic chronic rhinosinusitis in East Asians. World J Clin Cases. 2014;2(12):873–882.
    1. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–1440.
    1. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Resp Crit Care Med. 2009;180(5):388–395.
    1. Licari A, Castagnoli R, Brambilla I, Marseglia A, Tosca MA, Marseglia GL, et al. Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmanol. 2018;31(2):44–55.
    1. Svenningsen S, Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Front Med. 2017;4:158.
    1. Aleman F, Lim HF, Nair P. Eosinophilic endotype of asthma. Immunol Allergy Clin North Am. 2016;36(3):559–568.
    1. Qiu R, Xie J, Chung KF, Li N, Yang Z, He M, et al. Asthma phenotypes defined from parameters obtained during recovery from a hospital-treated exacerbation. J Allergy Clin Immunol Pract. 2018;6(6):1960–1967.
    1. Xie M, Wenzel SE. A global perspective in asthma: from phenotype to endotype. Chin Med J. 2013;126(1):166–174.
    1. Peng Y, Zi XX, Tian TF, Lee B, Lum J, Tang SA, et al. Whole-transcriptome sequencing reveals heightened inflammation and defective host defence responses in chronic rhinosinusitis with nasal polyps. Eur Respir J. 2019;54(5):1900732.
    1. Yan B, Lou H, Wang Y, Li Y, Meng Y, Qi S, et al. Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(2):455–469.
    1. Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, et al. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014;289(18):12623–12632.
    1. Yi L, Cheng D, Zhang K, Huo X, Mo Y, Shi H, et al. Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal Immunol. 2017;10(6):1491–1503.
    1. Daubeuf F, Jung F, Douglas GJ, Chevalier E, Frossard N. Protective effect of a Protein Epitope Mimetic CCR10 antagonist, POL7085, in a model of allergic eosinophilic airway inflammation. Respir Res. 2015;16:77.
    1. Pezato R, Swierczynska-Krepa M, Nizankowska-Mogilnicka E, Derycke L, Bachert C, Perez-Novo CA. Role of imbalance of eicosanoid pathways and staphylococcal superantigens in chronic rhinosinusitis. Allergy. 2012;67(11):1347–1356.
    1. Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med. 2008;14(10):461–469.
    1. Miyata J, Fukunaga K, Kawashima Y, Ohara O, Arita M. Cysteinyl leukotriene metabolism of human eosinophils in allergic disease. Allergol Int. 2020;69(1):28–34.
    1. Ishiura Y, Fujimura M, Nobata K, Oribe Y, Abo M, Myou S. Prostaglandin I2 enhances cough reflex sensitivity to capsaicin in the asthmatic airway. Cough. 2007;3:2.
    1. Harrington LS, Lucas R, McMaster SK, Moreno L, Scadding G, Warner TD, et al. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J. 2008;22(11):4005–4010.
    1. Magnusson LU, Lundqvist A, Karlsson MN, Skalen K, Levin M, Wiklund O, et al. Arachidonate 15-lipoxygenase type B knockdown leads to reduced lipid accumulation and inflammation in atherosclerosis. PLoS ONE. 2012;7(8):e43142.
    1. Samuchiwal SK, Boyce JA. Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology. J Allergy Clin Immunol. 2018;141(4):1182–1190.
    1. Devadoss D, Long C, Langley RJ, Manevski M, Nair M, Campos MA, et al. Long noncoding transcriptome in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2019;61(6):678–688.
    1. Schulte LN, Bertrams W, Stielow C, Schmeck B. NcRNAs in inflammatory and infectious diseases. Methods Mol Biol. 2019;1912:3–32.
    1. Yue L, Yin X, Hao F, Dong J, Ren X, Xu O, et al. Long Noncoding RNA Linc00632 Inhibits Interleukin-13-Induced inflammatory cytokine and mucus production in nasal epithelial cells. J Innate Immun. 2020;12(1):116–128.
    1. Wang W, Gao Z, Wang H, Li T, He W, Lv W, et al. Transcriptome analysis reveals distinct gene expression profiles in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyps. Sci Rep. 2016;6:26604.
    1. Liu H, Zhou T, Wang B, Li L, Ye D, Yu S. Identification and functional analysis of a potential key lncRNA involved in fat loss of cancer cachexia. J Cell Biochem. 2018;119(2):1679–1688.
    1. Duan H, Ge W, Zhang A, Xi Y, Chen Z, Luo D, et al. Transcriptome analyses reveal molecular mechanisms underlying functional recovery after spinal cord injury. Proc Natl Acad Sci USA. 2015;112(43):13360–13365.
    1. Esposti DD, Hernandez-Vargas H, Voegele C, Fernandez-Jimenez N, Forey N, Bancel B, et al. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Oncotarget. 2016;7(22):31862–31877.
    1. Carpenter S, Fitzgerald KA. Cytokines and long noncoding RNAs. Cold Spring Harb Perspect Biol. 2018;10(6):a028589.
    1. Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martinez JA, Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 2015;29(9):3595–3611.
    1. Ordovas-Montanes J, Dwyer DF, Nyquist SK, Buchheit KM, Vukovic M, Deb C, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018;560(7720):649–654.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner